Republic of Korea vs South Africa: Share of E. coli infections resistant to cephalosporins
Republic of Korea
38.8%
in 2022
South Africa
30.0%
in 2022
Republic of Korea rank
21st
South Africa rank
24th
Share of E. coli infections resistant to cephalosporins over time
- Republic of Korea
- South Africa
How they compare
Republic of Korea currently reports 38.8% against 30.0% in South Africa, a difference of 8.8%.
That makes Republic of Korea's figure about 1.3 times South Africa's.
Across all 5 years both countries report, Republic of Korea has been ahead every year.
Republic of Korea ranks 21st and South Africa ranks 24th of 46 countries.
Republic of Korea has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Republic of Korea | South Africa | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 37.9% | 30.6% | 7.3% | Republic of Korea |
| 2020s | 37.7% | 28.6% | 9.1% | Republic of Korea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of e. coli infections resistant to cephalosporins, Republic of Korea or South Africa?
- Republic of Korea, at 38.8% against 30.0% in South Africa as of 2022.
- What is the difference in share of e. coli infections resistant to cephalosporins between Republic of Korea and South Africa?
- 8.8%, with Republic of Korea ahead.
- How many years of comparable data are there for Republic of Korea and South Africa?
- 5 years are reported by both, from 2018 to 2022.
- How do Republic of Korea and South Africa rank globally for share of e. coli infections resistant to cephalosporins?
- Republic of Korea ranks 21st and South Africa ranks 24th of 46 countries.
- Where does this data come from?
- World Health Organization – processed by Our World in Data, published as Share of E. coli infections resistant to cephalosporins. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of bloodstream infection due to Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested (%).